
|Articles|September 6, 2007
ESC: On Second Go-Round, MERLIN Finds Arrhythmia Magic in Ranolazine
VIENNA -- The anti-anginal drug ranolazine (Ranexa) may reduce episodes of ventricular tachycardia and supraventricular tachycardia, researchers here reported.
Advertisement
VIENNA, Sept. 6 -- The anti-anginal drug ranolazine (Ranexa) may reduce episodes of ventricular tachycardia and supraventricular tachycardia, researchers reported here.
The potential benefit was detected in a pre-specified analysis of Holter monitor data from MERLIN-TIMI 36 -- a failed trial of ranolazine for treatment of acute coronary syndrome.
Yet the analysis showed that ranolazine reduced the number of ventricular tachycardia episodes by 37% (P
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
Reminders for Primary Care Physicians, Patients Improved Annual Lung Cancer Screening Adherence
2
FDA Approves Lerodalcibep Autoinjector for Hypercholesterolemia, Updated Indication
3
Relationship-Based Navigation Improves Resource Access in Primary Care Trial
4





























































































































































